Uniqure SEC Filings

Vestal Point Capital, LP and Ryan Wilder reported beneficial ownership of 3,700,000 ordinary shares of uniQure N.V., representing 6.8% of the outstanding class. The shares are directly held by a Vestal Point-managed fund and a managed account; Mr. Wilder is the Chief Investment Officer and managing partner of the investment manager and reports shared voting and dispositive power over the shares. The percent calculation uses 54,748,496 ordinary shares outstanding as of May 6, 2025. The filing states the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

RTW Investments, LP and Roderick Wong report a passive 9.4% stake in uniQure (QURE), holding 5,158,231 ordinary shares. The holdings are held directly by the RTW Funds and RTW Investments and Dr. Wong report shared voting and dispositive power over all 5,158,231 shares and report no sole voting or dispositive power. The percentage is calculated using 54,865,673 shares outstanding as reported for the period cited in the filing. The statement is made on a Schedule 13G basis and includes a certification that the shares were acquired and are held in the ordinary course of business and not to change or influence control of the issuer.

Avoro Capital Advisors LLC and Behzad Aghazadeh report holding 3,625,000 ordinary shares of uniQure N.V., representing 6.6% of the outstanding class. The percentage is calculated using 54,748,496 ordinary shares outstanding as of May 6, 2025. The filing states the shares were acquired and are held for investment purposes on behalf of Avoro Life Sciences Fund LLC, and that the reporting persons have sole voting and sole dispositive power over the reported shares. The statement also notes the filing should not be construed as an admission of beneficial ownership for Section 13 purposes. Avoro Life Sciences Fund LLC is identified as having the right to receive dividends or sale proceeds for the position.

Aberdeen Group plc and subsidiary abrdn Inc. have filed a Schedule 13G disclosing a new passive position in uniQure N.V. (QURE).

• Shares owned: 2,750,714 ordinary shares
• Ownership: 5.02 % of the outstanding class
• Voting/Dispositive power: 0 sole / 2,750,714 shared
• Event date: 30 Jun 2025   |  Filing signed: 30 Jul 2025
• SEC classifications: Aberdeen – Parent Holding Company (HC); abrdn Inc. – Investment Adviser & Corporation (IA, CO)
• Certification affirms the stake was acquired in the ordinary course and not intended to influence control.

The filing adds a sizeable institutional holder to uniQure’s share register, but because it is a 13G (passive) submission, it carries no stated activist intent.

uniQure N.V. (QURE) announced an at-the-market (ATM) equity offering program via Form 8-K. Under a new Sales Agreement dated 29 Jul 2025, Leerink Partners LLC will act as sales agent to place up to $200 million of ordinary shares (€0.05 par value) from time to time. Sales may occur on Nasdaq, other U.S. trading venues or through negotiated transactions, and will be executed on a “commercially reasonable efforts” basis.

Key terms:

• Commission: up to 3.0% of gross proceeds to Leerink Partners.
• No obligation: uniQure can choose whether, when and how much stock to sell; the agreement terminates after all shares are sold or upon earlier termination by the parties.
• Registration: shares will be issued under the company’s effective shelf registration statement (Form S-3ASR, File No. 333-284168).
• Legal opinions & exhibits: Sales Agreement (Ex. 1.1), legal opinion (Ex. 5.1) and related consents filed.

The facility enhances capital-raising flexibility but may dilute existing shareholders if fully utilized. No immediate share issuance or financial impact is disclosed.

uniQure N.V. (QURE) filed a prospectus supplement for an “at-the-market” equity program of up to $200 million in ordinary shares, par €0.05, to be sold from time to time through Leerink Partners LLC.

Leerink will act as sales agent and is entitled to a commission of up to 3 % of gross proceeds and will be treated as an underwriter. Shares will be issued on The Nasdaq Global Select Market at prevailing prices. Using the 25-Jul-2025 close of $15.11, a full draw would add roughly 13.24 m shares, lifting total shares outstanding to 68.10 m.

• Post-offering pro-forma net tangible book value rises from −$2.08 to $1.17 per share, creating immediate dilution of $13.94 for new investors.
• Proceeds will fund the potential U.S. launch of lead gene-therapy AMT-130, advance multiple clinical programs (AMT-260, AMT-191, AMT-162), support business development and general corporate needs.
• Risk highlights: discretionary use of funds, potential share-price pressure from sales, extensive outstanding equity awards, PFIC classification for 2024, no dividend policy and share-price volatility.

There is no minimum sale requirement and proceeds are not escrowed, giving the company flexibility but leaving investors uncertain about timing and pricing of dilution.